942232-53-3

Upstream product

• 18437-64-4 tert-butyl (3-nitrophenyl)carbamate 
• 96-32-2 bromoacetic acid methyl ester 
• 3320-87-4 isocyanic acid (3-nitro-phenyl) ester 

Downstream Products

• 528883-12-7 ((3-amino-phenyl)-tert-butoxycarbonyl-amino)-acetic acid methyl ester 
• 942232-11-3 C₃₆H₄₇N₅O₇ 
• 528883-11-6 (tert-butoxycarbonyl-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-amino)-acetic acid 

Relevant academic research and scientific papers

Optimization of 1,3,4-benzotriazepine-based CCK2 antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion

Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over

Anti-tumor compounds

The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula: STR1 wherein R1 includes hydrogen, amino and alkyl or alkoxy each of up to 4 carbon atoms; R2 includes hydrogen, alkyl, hydroxyalkyl and halogenoalkyl each of up to 4 carbon atoms; R3 is hydrogen or alkyl or up to 3 carbon atoms; Ar is phenylene or heterocyclene; L is a group of the formula --CO.NH--, --NH.CO--, --CO.NR4 --, --NR4.CO--, --CH=CH-- or --CO.O--, wherein R4 is alkyl of up to 4 carbon atoms; and Y is a branched alkyl group bearing substituents Y2 and Y3 the definition of each independently including hydroxy, cyano, aryl and heteroaryl, and the definition of Y3 also optionally including sulpho, N-phenylsulphonylcarbamoyl and 5-tetrazolyl; or a pharmaceutically-acceptable salt thereof.